| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, Illinois 60611
Address all correspondence and requests for reprints to: J. Larry Jameson, M.D., Ph.D., Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Tarry 15709, 303 East Chicago Avenue, Chicago, Illinois 60611. E-mail: ljameson{at}nwu.edu
The syndrome of resistance to thyroid hormone (RTH) is caused by multiple distinct mutations in the ligand-binding domain of the thyroid hormone receptor-ß (TRß). Although the mutant receptors are transcriptionally inactive, they inhibit normal receptor function in a dominant negative manner to cause hormone resistance. Recently, a group of transcriptional cofactors, referred to as corepressors (CoRs), was shown to induce ligand-independent silencing of genes that contain positive T3 response elements. CoRs also play a role in the ligand-independent basal activation of genes that are negatively regulated in response to T3. We hypothesized that CoR might play a role in the dominant negative inhibition by TRß mutants that cause RTH. In gel mobility shift assays, RTH mutants retained interactions with CoRs even in the presence of T3, whereas the ligand dissociated CoR from wild-type TRß. Using Gal4-TR chimeric receptors and a VP16-CoR fusion protein in an interaction assay, a strong positive correlation was found between mutant receptor interactions with CoR and transcriptional silencing activity. A mutation (P214R) that impairs CoR interactions with TR was introduced into the RTH mutants to assess the role of CoR in dominant negative activity. In transient transfection assays, introduction of the P214R CoR mutation decreased RTH mutant silencing of positively regulated genes and basal activation of negatively regulated genes. The dominant negative activity of several different RTH mutants, studied by cotransfection with wild-type receptor, was greatly diminished by the CoR mutation, and this effect was seen with both positively and negatively regulated genes. These results suggest that CoR interactions play a critical role in the dominant negative effect of RTH mutants and support the idea that these proteins are involved in the regulation of genes that are positively as well as negatively regulated by T3.
This article has been cited by other articles:
![]() |
D. S. Machado, A. Sabet, L. A. Santiago, A. R. Sidhaye, M. I. Chiamolera, T. M. Ortiga-Carvalho, and F. E. Wondisford From the Cover: A thyroid hormone receptor mutation that dissociates thyroid hormone regulation of gene expression in vivo PNAS, June 9, 2009; 106(23): 9441 - 9446. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tagami, H. Yamamoto, K. Moriyama, K. Sawai, T. Usui, A. Shimatsu, and M. Naruse The retinoid X receptor binding to the thyroid hormone receptor: relationship with cofactor binding and transcriptional activity J. Mol. Endocrinol., May 1, 2009; 42(5): 415 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tagami, H. Yamamoto, K. Moriyama, K. Sawai, T. Usui, A. Shimatsu, and M. Naruse A Selective Peroxisome Proliferator-Activated Receptor-{gamma} Modulator, Telmisartan, Binds to the Receptor in a Different Fashion from Thiazolidinediones Endocrinology, February 1, 2009; 150(2): 862 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Astapova, L. J. Lee, C. Morales, S. Tauber, M. Bilban, and A. N. Hollenberg The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo PNAS, December 9, 2008; 105(49): 19544 - 19549. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Wu, R. N. Cohen, E. Simsek, D. A. Senses, N. E. Yar, H. Grasberger, J. Noel, S. Refetoff, and R. E. Weiss A Novel Thyroid Hormone Receptor-{beta} Mutation That Fails to Bind Nuclear Receptor Corepressor in a Patient as an Apparent Cause of Severe, Predominantly Pituitary Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1887 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Araki, H. Ying, F. Furuya, X. Zhu, and S.-y. Cheng Thyroid hormone receptor {beta} mutants: Dominant negative regulators of peroxisome proliferator-activated receptor {gamma} action PNAS, November 8, 2005; 102(45): 16251 - 16256. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wan, B. Farboud, and M. L. Privalsky Pituitary Resistance to Thyroid Hormone Syndrome Is Associated with T3 Receptor Mutants that Selectively Impair {beta}2 Isoform Function Mol. Endocrinol., June 1, 2005; 19(6): 1529 - 1542. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lado-Abeal, A. M. Dumitrescu, X.-H. Liao, R. N. Cohen, J. Pohlenz, R. E. Weiss, M.-C. Lebrethon, A. Verloes, and S. Refetoff A De Novo Mutation in an Already Mutant Nucleotide of the Thyroid Hormone Receptor {beta} Gene Perpetuates Resistance to Thyroid Hormone J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1760 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Gonzalez, P. Samenfeld, M. Perakyla, and C. Carlberg Corepressor Excess Shifts the Two-Side Chain Vitamin D Analog Gemini from an Agonist to an Inverse Agonist of the Vitamin D Receptor Mol. Endocrinol., October 1, 2003; 17(10): 2028 - 2038. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Farboud, H. Hauksdottir, Y. Wu, and M. L. Privalsky Isotype-Restricted Corepressor Recruitment: a Constitutively Closed Helix 12 Conformation in Retinoic Acid Receptors {beta} and {gamma} Interferes with Corepressor Recruitment and Prevents Transcriptional Repression Mol. Cell. Biol., April 15, 2003; 23(8): 2844 - 2858. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marimuthu, W. Feng, T. Tagami, H. Nguyen, J. L. Jameson, R. J. Fletterick, J. D. Baxter, and B. L. West TR Surfaces and Conformations Required to Bind Nuclear Receptor Corepressor Mol. Endocrinol., February 1, 2002; 16(2): 271 - 286. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ando, N. J. Sarlis, E. H. Oldfield, and P. M. Yen Somatic Mutation of TR{beta} Can Cause a Defect in Negative Regulation of TSH in a TSH-Secreting Pituitary Tumor J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5572 - 5576. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ando, N. J. Sarlis, J. Krishnan, X. Feng, S. Refetoff, M. Q. Zhang, E. H. Oldfield, and P. M. Yen Aberrant Alternative Splicing of Thyroid Hormone Receptor in a TSH-Secreting Pituitary Tumor Is A Mechanism for Hormone Resistance Mol. Endocrinol., September 1, 2001; 15(9): 1529 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Yen Physiological and Molecular Basis of Thyroid Hormone Action Physiol Rev, July 1, 2001; 81(3): 1097 - 1142. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Reutrakul, P. M. Sadow, S. Pannain, J. Pohlenz, G. A. Carvalho, P. E. Macchia, R. E. Weiss, and S. Refetoff Search for Abnormalities of Nuclear Corepressors, Coactivators, and a Coregulator in Families with Resistance to Thyroid Hormone without Mutations in Thyroid Hormone Receptor {beta} or {alpha} Genes J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3609 - 3617. [Abstract] [Full Text] |
||||
![]() |
L. J. BURKE and A. BANIAHMAD Co-repressors 2000 FASEB J, October 1, 2000; 14(13): 1876 - 1888. [Abstract] [Full Text] |
||||
![]() |
Q.-L. Li, E. Jansen, G. A. Brent, S. Naqvi, J. F. Wilber, and T. C. Friedman Interactions between the Prohormone Convertase 2 Promoter and the Thyroid Hormone Receptor Endocrinology, September 1, 2000; 141(9): 3256 - 3266. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Y. Chien, M. Ito, Y. Park, T. Tagami, B. D. Gehm, and J. L. Jameson A Fusion Protein of the Estrogen Receptor (ER) and Nuclear Receptor Corepressor (NCoR) Strongly Inhibits Estrogen-Dependent Responses in Breast Cancer Cells Mol. Endocrinol., December 1, 1999; 13(12): 2122 - 2136. [Abstract] [Full Text] |
||||
![]() |
J. Zhang, X. Hu, and M. A. Lazar A Novel Role for Helix 12 of Retinoid X Receptor in Regulating Repression Mol. Cell. Biol., September 1, 1999; 19(9): 6448 - 6457. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tagami, Y. Park, and J. L. Jameson Mechanisms That Mediate Negative Regulation of the Thyroid-stimulating Hormone alpha Gene by the Thyroid Hormone Receptor J. Biol. Chem., August 6, 1999; 274(32): 22345 - 22353. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Thacher, S. Nagpal, E. S. Klein, T. Arefieg, G. Krasinski, D. DiSepio, C. Agarwal, A. Johnson, R. L. Eckert, and R. A. S. Chandraratna Cell Type and Gene-specific Activity of the Retinoid Inverse Agonist AGN 193109: Divergent Effects from Agonist at Retinoic Acid Receptor {{gamma}} in Human Keratinocytes Cell Growth Differ., April 1, 1999; 10(4): 255 - 262. [Abstract] [Full Text] |
||||
![]() |
T. Tagami, W.-X. Gu, P. T. Peairs, B. L. West, and J. L. Jameson A Novel Natural Mutation in the Thyroid Hormone Receptor Defines a Dual Functional Domain That Exchanges Nuclear Receptor Corepressors and Coactivators Mol. Endocrinol., December 1, 1998; 12(12): 1888 - 1902. [Abstract] [Full Text] |
||||
![]() |
J. D. Safer, R. N. Cohen, A. N. Hollenberg, and F. E. Wondisford Defective Release of Corepressor by Hinge Mutants of the Thyroid Hormone Receptor Found in Patients with Resistance to Thyroid Hormone J. Biol. Chem., November 13, 1998; 273(46): 30175 - 30182. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tagami, P. Kopp, W. Johnson, O. K. Arseven, and J. L. Jameson The Thyroid Hormone Receptor Variant {alpha}2 Is a Weak Antagonist because It Is Deficient in Interactions with Nuclear Receptor Corepressors Endocrinology, May 1, 1998; 139(5): 2535 - 2544. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Yoh and M. L. Privalsky Transcriptional Repression by Thyroid Hormone Receptors. A ROLE FOR RECEPTOR HOMODIMERS IN THE RECRUITMENT OF SMRT COREPRESSOR J. Biol. Chem., May 11, 2001; 276(20): 16857 - 16867. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |